Antioxidant Enzyme SOD3 Dampens Allergy-Linked Inflammation in Lab-Grown Epithelial Cells

An extracellular antioxidant enzyme may help rein in the type 2 inflammatory signalling that drives allergic skin and airway disease, according to a cell-culture study published in 3 Biotech. The research shows that superoxide dismutase 3, or SOD3, suppresses the matricellular protein periostin in human keratinocytes and bronchial epithelial cells exposed to the interleukin-4 and interleukin-13 cytokines that characterise type 2 inflammation. By quieting periostin, the enzyme blunted a cascade of downstream inflammatory signals in both cell types, pointing to a previously underappreciated role for this antioxidant protein in epithelial immunity.

The team, led by Gia-Buu Tran, Nguyen Hoai Nguyen, Tae-Yoon Kim and Cuong Thach Nguyen, worked with two widely used human cell lines: HaCaT keratinocytes, which model the skin’s outer barrier, and BEAS-2B bronchial epithelial cells, which line the airways. When the cells were stimulated with IL-4 and IL-13, SOD3 significantly reduced periostin expression at both the mRNA and protein levels. Suppressing a secreted matrix protein in response to type 2 cytokine stimulation made periostin a biologically meaningful endpoint rather than an incidental side effect.

Mechanistically, the study traced the effect to the entry point of the type 2 cytokine pathway. SOD3 physically interacted with the interleukin-4 receptor alpha subunit, IL-4Rα, and weakened activation of the Janus kinase/signal transducer and activator of transcription 6 pathway that lies immediately downstream. With STAT6 signalling attenuated, the cell produced less periostin.

Knocking periostin down directly, and then adding recombinant periostin back to the cultures, allowed the researchers to confirm that most of SOD3’s downstream influence flowed through this axis. The enzyme reduced phosphorylation of nuclear factor-κB, p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and c-Jun N-terminal kinase largely through periostin suppression, an experimental design that separates correlation from causation within the measured pathway.

The consequences extended across a network of inflammatory mediators. In SOD3-treated cells, expression of periostin-associated molecules fell, including vascular endothelial growth factor, thymic stromal lymphopoietin, transforming growth factor-β and matrix metalloproteinases. The enzyme also curbed the production of the pro-inflammatory cytokines tumour necrosis factor-α, interleukin-1β and interleukin-6 that periostin normally induces.

Together, these results sketch a coherent signalling map in which SOD3 acts at the receptor level, restrains STAT6-driven periostin output, and thereby softens the NF-κB and MAPK responses that amplify epithelial inflammation. Because the same pattern appeared in both keratinocytes and bronchial epithelial cells, the authors argue that the mechanism is not confined to a single barrier tissue in culture.

The authors suggest that SOD3 attenuates IL-4/IL-13-driven epithelial inflammation at least in part through modulation of the IL-4Rα/JAK/STAT6/periostin axis and the downstream NF-κB/MAPK pathways, and they propose the enzyme as a potential therapeutic candidate for type 2 inflammatory diseases. The evidence, however, comes entirely from laboratory cell lines, and the study does not report animal or human data. Whether SOD3 can reach and modulate these pathways in inflamed skin or airway tissue in living organisms remains untested.

Still, the work adds mechanistic depth to the abstract’s description of SOD3 as an extracellular antioxidant enzyme with an emerging role in the regulation of inflammatory responses, positioning it as a regulator that may sit at the junction of redox balance and cytokine signalling in barrier tissues. If future studies extend the findings beyond culture dishes, the IL-4Rα/JAK/STAT6/periostin axis could offer a defined molecular target for therapies aimed at type 2 inflammatory disease.

Subject of Research: Superoxide dismutase 3 (SOD3) suppresses periostin to attenuate IL-4/IL-13-driven epithelial inflammation

Article Title: Superoxide dismutase 3 (SOD3) suppresses periostin to attenuate IL-4/IL-13-driven epithelial inflammation

Article References: Tran, G.-B., Nguyen, N. H., Kim, T.-Y., & Nguyen, C. T. (2026). Superoxide dismutase 3 (SOD3) suppresses periostin to attenuate IL-4/IL-13-driven epithelial inflammation. 3 Biotech, 16(11), 478. https://doi.org/10.1007/s13205-026-05112-3

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05112-3

Keywords: Superoxide, dismutase, SOD3, suppresses, periostin, attenuate, IL-4, IL-13-driven, epithelial, inflammation, scientific research